scholarly journals Effective bowel motion reduction in mouse abdominal MRI using hyoscine butylbromide

2021 ◽  
Author(s):  
Carlos Bilreiro ◽  
Francisca F. Fernandes ◽  
Luísa Andrade ◽  
Cristina Chavarrías ◽  
Rui V. Simões ◽  
...  
Keyword(s):  
Hyoscine Butylbromide ◽  
Abdominal Mri ◽  
Bowel Motion

scholarly journals A feasibility study of hyoscine butylbromide (buscopan) to improve image quality of cone beam computed tomography during abdominal/pelvic Stereotactic Ablative Radiotherapy

BJR|Open ◽  
2021 ◽  
Vol 3 (1) ◽  
pp. 20210045
Author(s):  
Finbar Slevin ◽  
Matthew Beasley ◽  
Jim Zhong ◽  
Eleanor Hudson ◽  
Richard Speight ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Image Quality ◽  
Cone Beam Computed Tomography ◽  
Feasibility Trial ◽  
Cone Beam ◽  
Stereotactic Ablative Radiotherapy ◽  
Motion Artefact ◽  
Hyoscine Butylbromide ◽  
Bowel Motion ◽  
The Impact

Objectives: Cone beam computed tomography (CBCT) is used for image guidance of stereotactic ablative radiotherapy (SABR), but it is susceptible to bowel motion artefacts. This trial evaluated the impact of hyoscine butylbromide (buscopan) on CBCT image quality and its feasibility within a radiotherapy workflow. Methods: A single-centre feasibility trial (ISRCTN24362767) was performed in patients treated with SABR for abdominal/pelvic oligorecurrence. Buscopan was administered to separate cohorts by intramuscular (IM) or intravenous (i.v.) injection on alternate fractions, providing within-patient control data. 4-point Likert scales were used to assess overall image quality (ranging from excellent to impossible to use) and bowel motion artefact (ranging from none to severe). Feasibility was determined by patient/radiographer questionnaires and toxicity assessment. Descriptive statistics are presented. Results: 16 patients were treated (8 by IM and 8 by i.v. buscopan). The percentage of images of excellent quality with/without buscopan was 47 vs 29% for IM buscopan and 65 vs 40% for i.v. buscopan. The percentage of images with no bowel motion artefact with/without buscopan was 24.6 vs 8.9% for IM buscopan and 25.8 vs 7% for i.v. buscopan. Four patients (25%) reported dry mouth. 14 patients (93%) would accept buscopan as routine. 11 radiographers (92%) reported no delay in treatments. Conclusions: A trend towards improved image quality/reduced bowel motion artefact was observed with IM/i.v. buscopan. Buscopan was well tolerated with limited impact on workflow. Advances in knowledge: This is the first trial of buscopan within a radiotherapy workflow. It demonstrated a trend to improved image quality and feasibility of use.

Hyoscine butylbromide während der Prostata-MRT-Akquisition reduziert signifikant Bewegungsartefakte und verbessert die anatomische Abgrenzbarkeit

2018 ◽  
Author(s):  
L Schimmöller ◽  
T Ullrich ◽  
A Schmaltz ◽  
M Klingebiehl ◽  
M Quentin ◽  
...  
Keyword(s):  
Hyoscine Butylbromide

scholarly journals Role of Radiotherapy in Recurrent Intra-Abdominal Yolk Sac Tumor

2021 ◽  
pp. 1010-1018
Author(s):  
Marhendra Satria Utama ◽  
Andi Kurniadi ◽  
A.A. Citra Yunda Prahastiwi ◽  
Antony A. Adibrata
Keyword(s):  
Case Reports ◽  
Yolk Sac ◽  
Yolk Sac Tumor ◽  
Appropriate Treatment ◽  
Curative Radiotherapy ◽  
Chief Complaints ◽  
Abdominal Mri ◽  
Malignant Germ Cell Tumor

Yolk sac tumor (YST) is a rare malignant germ cell tumor with no appropriate treatment strategy to date. However, patients are treated on a case-to-case basis as per various case reports that have been published. Here, we present a case of 27-year-old female patient who presented to us with chief complaints of severe abdominal pain associated with leucorrhea. She previously had a similar pain episode, which was then evaluated by a multidisciplinary team. She was diagnosed with YST. After that, she underwent 6 cycles of chemotherapy, but there was no improvement. Then the medical oncologist referred her to performed radiotherapy. Then, the radiation oncologist decided to give her curative radiotherapy of 3D-CRT. After completing her sessions, she felt better and clinically improving. After that, she was discharged and scheduled a follow-up visit for first evaluation. At her follow-up visit, she was feeling well, and we decided to have an abdominal MRI.

scholarly journals Applying MRI Intensity Normalization on Non-Bone Tissues to Facilitate Pseudo-CT Synthesis from MRI

Diagnostics ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 816
Author(s):  
Kuei-Yuan Hou ◽  
Hao-Yuan Lu ◽  
Ching-Ching Yang
Keyword(s):  
Mean Value ◽  
Tissue Type ◽  
Routine Practice ◽  
Intensity Level ◽  
Mean Values ◽  
Conversion Model ◽  
Ratio Image ◽  
Abdominal Mri ◽  
High Level ◽  
Intensity Normalization

This study aimed to facilitate pseudo-CT synthesis from MRI by normalizing MRI intensity of the same tissue type to a similar intensity level. MRI intensity normalization was conducted through dividing MRI by a shading map, which is a smoothed ratio image between MRI and a three-intensity mask. Regarding pseudo-CT synthesis from MRI, a conversion model based on a three-layer convolutional neural network was trained and validated. Before MRI intensity normalization, the mean value ± standard deviation of fat tissue in 0.35 T chest MRI was 297 ± 73 (coefficient of variation (CV) = 24.58%), which was 533 ± 91 (CV = 17.07%) in 1.5 T abdominal MRI. The corresponding results were 149 ± 32 (CV = 21.48%) and 148 ± 28 (CV = 18.92%) after intensity normalization. With regards to pseudo-CT synthesis from MRI, the differences in mean values between pseudo-CT and real CT were 3, 15, and 12 HU for soft tissue, fat, and lung/air in 0.35 T chest imaging, respectively, while the corresponding results were 3, 14, and 15 HU in 1.5 T abdominal imaging. Overall, the proposed workflow is reliable in pseudo-CT synthesis from MRI and is more practicable in clinical routine practice compared with deep learning methods, which demand a high level of resources for building a conversion model.

Limited abdominal MRI in the evaluation of acute right upper quadrant pain

2003 ◽  
Vol 28 (5) ◽  
pp. 643-651 ◽  
Author(s):  
K. Y. Oh ◽  
M. Gilfeather ◽  
A. Kennedy ◽  
C. Glastonbury ◽  
D. Green ◽  
...  
Keyword(s):  
Quadrant Pain ◽  
Abdominal Mri

The effect of Hyoscine Butylbromide on the rate of vaginal delivery in cases of secondary arrest of cervical dilatation: A rondomized controlled clinical trial

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Mohamed Ahmed Elkady ◽  
Dina Yahia Mansour ◽  
Alyaa Mostafa Elshamy
Keyword(s):  
Vaginal Delivery ◽  
Statistical Difference ◽  
Saline Group ◽  
Cervical Dilatation ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Hyoscine Butylbromide ◽  
Labor Time ◽  
Significant Statistical Difference ◽  
Significant Difference

Abstract Background For decades, health providers have worked to manage labor actively and safely, with the goal of shortening the duration of painful labor. Reduction of cesarean sections and maternal complication is also an important aspect of labor management. Antispasmodic are commonly administrating during labor in both developing and developed countries, although there is a paucity of scientific reports validating this. Hyoscine butylbromide is an effective antispasmodic drug. Therefore, We aim to assess efficacy of Hyoscine butylbromide on rate of vaginal delivery in cases of 2ry arrest of cervical dilatation. Objective To assess whether the intravenous injection of hyoscine butylbromide is effective in progress of labor in which cases with 2ry arrest of cervical dilatation. Patients and Methods The study included 100 pregnant women (PG, P1, P2, P3) conducted at Ain Shams University Maternity Hospital, the inclusion Criteria were: term uncomplicated singleton pregnancy in a spontaneous active labor, with cephalic presentation. The patient must be free from any medical disorder associated with pregnancy and free from any obstetric complication. Cases were subdivided into 2 groups: Study group: 50 patients received 40mg iv Hyoscine Butylbromide (as Buscopan 20mg\mrl) when the cervix >4cm dilated and was >50% effaced. Control group: 50 patients received 2ml saline as placebo. Results Significant increase in vaginal delivery rate (72%) in Hyoscine group; compared to Saline group (52%); with significant statistical difference (p = 0.04). Highly significant decrease in 1st and 2nd stage labor time in Hyoscine group; compared to Saline group; with highly significant statistical difference (p < 0.05 respectively). These results observed without significant difference as regards 3rd stage labor time and postpartum hemorrhage (p > 0.05), APGAR score and NICU admission (p > 0.05). Conclusion From the current study we can conclude that HBB 40 mg is safe and effective in increasing vaginal delivary rate in cases of 2ry arrest of 12 dilatation. It is effective in decreasing first and second stage of labor. It has no maternal or neonatal adverse effect. It is easy and available.

Sign in / Sign up

Export Citation Format

Share Document